Written by MarketBeatUpdated September 11, 2025 ShareLink copied to clipboard. Key Points Arteris has been downgraded by Wall Street Zen from a "hold" rating to a "sell" rating, indicating a shift in market sentiment regarding the company's stock. While Wall Street Zen has issued a sell rating, other analysts, including Rosenblatt Securities and TD Cowen, have maintained buy ratings with price targets ranging from $14.00 to $15.00. Insider trading activities reveal that significant shareholders, including major shareholder Bayview Legacy and CEO K. Charles Janac, have sold substantial amounts of stock recently, indicating potential concerns over the company's future performance. Five stocks to consider instead of Arteris. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and Offers2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025October 16 Changes the Microchip Game — and InvestingFrom Banyan Hill Publishing (Ad)What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 2025Alibaba Group Holding Limited $BABA is Temasek Holdings Private Ltd's 10th Largest PositionBy MarketBeat | September 11, 2025Trump’s $5.3 Trillion “Manhattan Project”From Angel Publishing (Ad)Silver and Gold Break Out—3 Names to Ride the WaveBy Gabriel Osorio-Mazilli | September 6, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated September 11, 2025 ShareLink copied to clipboard. Key Points Arteris has been downgraded by Wall Street Zen from a "hold" rating to a "sell" rating, indicating a shift in market sentiment regarding the company's stock. While Wall Street Zen has issued a sell rating, other analysts, including Rosenblatt Securities and TD Cowen, have maintained buy ratings with price targets ranging from $14.00 to $15.00. Insider trading activities reveal that significant shareholders, including major shareholder Bayview Legacy and CEO K. Charles Janac, have sold substantial amounts of stock recently, indicating potential concerns over the company's future performance. Five stocks to consider instead of Arteris. Like this article? Share it with a colleague. Link copied to clipboard.
